These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22272611)

  • 1. Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD.
    Egan M; Yaari R; Liu L; Ryan M; Peng Y; Lines C; Michelson D
    Curr Alzheimer Res; 2012 May; 9(4):481-90. PubMed ID: 22272611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).
    Veroff AE; Bodick NC; Offen WW; Sramek JJ; Cutler NR
    Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):304-12. PubMed ID: 9876958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia.
    F Egan M; Zhao X; Gottwald R; Harper-Mozley L; Zhang Y; Snavely D; Lines C; Michelson D
    Schizophr Res; 2013 May; 146(1-3):224-30. PubMed ID: 23523692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder.
    Herring WJ; Wilens TE; Adler LA; Baranak C; Liu K; Snavely DB; Lines CR; Michelson D
    J Clin Psychiatry; 2012 Jul; 73(7):e891-8. PubMed ID: 22901359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
    Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
    J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
    Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
    Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease.
    Galasko D; Bell J; Mancuso JY; Kupiec JW; Sabbagh MN; van Dyck C; Thomas RG; Aisen PS;
    Neurology; 2014 Apr; 82(17):1536-42. PubMed ID: 24696507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study.
    Herring WJ; Liu K; Hutzelmann J; Snavely D; Snyder E; Ceesay P; Lines C; Michelson D; Roth T
    Sleep Med; 2013 Oct; 14(10):955-63. PubMed ID: 23920422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.
    Aisen PS; Schneider LS; Sano M; Diaz-Arrastia R; van Dyck CH; Weiner MF; Bottiglieri T; Jin S; Stokes KT; Thomas RG; Thal LJ;
    JAMA; 2008 Oct; 300(15):1774-83. PubMed ID: 18854539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease.
    Schwam EM; Nicholas T; Chew R; Billing CB; Davidson W; Ambrose D; Altstiel LD
    Curr Alzheimer Res; 2014; 11(5):413-21. PubMed ID: 24801218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
    Frölich L; Ashwood T; Nilsson J; Eckerwall G;
    J Alzheimers Dis; 2011; 24(2):363-74. PubMed ID: 21258153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
    Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
    Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles.
    Le Bars PL
    Pharmacopsychiatry; 2003 Jun; 36 Suppl 1():S50-5. PubMed ID: 13130389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
    Buchanan RW; Keefe RS; Lieberman JA; Barch DM; Csernansky JG; Goff DC; Gold JM; Green MF; Jarskog LF; Javitt DC; Kimhy D; Kraus MS; McEvoy JP; Mesholam-Gately RI; Seidman LJ; Ball MP; McMahon RP; Kern RS; Robinson J; Marder SR
    Biol Psychiatry; 2011 Mar; 69(5):442-9. PubMed ID: 21145041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
    Sevigny JJ; Ryan JM; van Dyck CH; Peng Y; Lines CR; Nessly ML;
    Neurology; 2008 Nov; 71(21):1702-8. PubMed ID: 19015485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
    Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
    Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.
    Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Petanceska S; Browne P; Wassar D; Johnson-Traver S; Lochhead J; Ziolkowski C
    Curr Alzheimer Res; 2005 Jul; 2(3):343-53. PubMed ID: 15974900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.